Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Preactive lesions in multiple sclerosis.

van der Valk P, Amor S.

Curr Opin Neurol. 2009 Jun;22(3):207-13. doi: 10.1097/WCO.0b013e32832b4c76. Review.

PMID:
19417567
2.

Clusters of activated microglia in normal-appearing white matter show signs of innate immune activation.

van Horssen J, Singh S, van der Pol S, Kipp M, Lim JL, Peferoen L, Gerritsen W, Kooi EJ, Witte ME, Geurts JJ, de Vries HE, Peferoen-Baert R, van den Elsen PJ, van der Valk P, Amor S.

J Neuroinflammation. 2012 Jul 2;9:156. doi: 10.1186/1742-2094-9-156.

3.

Preactive multiple sclerosis lesions offer novel clues for neuroprotective therapeutic strategies.

van Noort JM, van den Elsen PJ, van Horssen J, Geurts JJ, van der Valk P, Amor S.

CNS Neurol Disord Drug Targets. 2011 Feb;10(1):68-81. Review.

PMID:
21143143
4.

Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons.

Singh S, Metz I, Amor S, van der Valk P, Stadelmann C, Brück W.

Acta Neuropathol. 2013 Apr;125(4):595-608. doi: 10.1007/s00401-013-1082-0. Epub 2013 Jan 26.

5.

Pathological abnormalities in the normal-appearing white matter in multiple sclerosis.

Allen IV, McQuaid S, Mirakhur M, Nevin G.

Neurol Sci. 2001 Apr;22(2):141-4. Review.

PMID:
11603615
6.

Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions.

van Noort JM, Bsibsi M, Gerritsen WH, van der Valk P, Bajramovic JJ, Steinman L, Amor S.

J Neuropathol Exp Neurol. 2010 Jul;69(7):694-703. doi: 10.1097/NEN.0b013e3181e4939c.

PMID:
20535035
7.

Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis.

Vos CM, Geurts JJ, Montagne L, van Haastert ES, Bö L, van der Valk P, Barkhof F, de Vries HE.

Neurobiol Dis. 2005 Dec;20(3):953-60. Epub 2005 Jul 21.

PMID:
16039866
8.

Homogeneity of active demyelinating lesions in established multiple sclerosis.

Breij EC, Brink BP, Veerhuis R, van den Berg C, Vloet R, Yan R, Dijkstra CD, van der Valk P, Bö L.

Ann Neurol. 2008 Jan;63(1):16-25. doi: 10.1002/ana.21311.

PMID:
18232012
9.

Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions.

Gobin SJ, Montagne L, Van Zutphen M, Van Der Valk P, Van Den Elsen PJ, De Groot CJ.

Glia. 2001 Oct;36(1):68-77.

PMID:
11571785
10.

Alpha-B-crystallin induces an immune-regulatory and antiviral microglial response in preactive multiple sclerosis lesions.

Bsibsi M, Holtman IR, Gerritsen WH, Eggen BJ, Boddeke E, van der Valk P, van Noort JM, Amor S.

J Neuropathol Exp Neurol. 2013 Oct;72(10):970-9. doi: 10.1097/NEN.0b013e3182a776bf.

PMID:
24042199
11.

The pathologic substrate of magnetic resonance alterations in multiple sclerosis.

Lassmann H.

Neuroimaging Clin N Am. 2008 Nov;18(4):563-76, ix. doi: 10.1016/j.nic.2008.06.005. Review.

PMID:
19068402
12.

Hypoperfusion of the cerebral white matter in multiple sclerosis: possible mechanisms and pathophysiological significance.

De Keyser J, Steen C, Mostert JP, Koch MW.

J Cereb Blood Flow Metab. 2008 Oct;28(10):1645-51. doi: 10.1038/jcbfm.2008.72. Epub 2008 Jul 2. Review.

PMID:
18594554
13.

Increased expression of distinct galectins in multiple sclerosis lesions.

Stancic M, van Horssen J, Thijssen VL, Gabius HJ, van der Valk P, Hoekstra D, Baron W.

Neuropathol Appl Neurobiol. 2011 Oct;37(6):654-71. doi: 10.1111/j.1365-2990.2011.01184.x.

PMID:
21501208
14.

Influence of neurosteroids on the pathogenesis of multiple sclerosis.

Leitner H.

Med Hypotheses. 2010 Aug;75(2):229-34. doi: 10.1016/j.mehy.2010.02.028. Epub 2010 Mar 12. Review.

PMID:
20227191
15.

Cortical pathology in multiple sclerosis.

Stadelmann C, Albert M, Wegner C, Brück W.

Curr Opin Neurol. 2008 Jun;21(3):229-34. doi: 10.1097/01.wco.0000318863.65635.9a. Review.

PMID:
18451703
16.

Progranulin expression in brain tissue and cerebrospinal fluid levels in multiple sclerosis.

Vercellino M, Grifoni S, Romagnolo A, Masera S, Mattioda A, Trebini C, Chiavazza C, Caligiana L, Capello E, Mancardi GL, Giobbe D, Mutani R, Giordana MT, Cavalla P.

Mult Scler. 2011 Oct;17(10):1194-201. doi: 10.1177/1352458511406164. Epub 2011 May 25.

17.

The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS.

Reynolds R, Dawson M, Papadopoulos D, Polito A, Di Bello IC, Pham-Dinh D, Levine J.

J Neurocytol. 2002 Jul-Aug;31(6-7):523-36.

PMID:
14501221
18.

Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter.

Markoullis K, Sargiannidou I, Schiza N, Hadjisavvas A, Roncaroli F, Reynolds R, Kleopa KA.

Acta Neuropathol. 2012 Jun;123(6):873-86. doi: 10.1007/s00401-012-0978-4. Epub 2012 Apr 7.

PMID:
22484441
19.

Review: the architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis.

Lassmann H.

Neuropathol Appl Neurobiol. 2011 Dec;37(7):698-710. doi: 10.1111/j.1365-2990.2011.01189.x. Review.

PMID:
21696413
20.

Oligodendrocytes and the early multiple sclerosis lesion.

Prineas JW, Parratt JD.

Ann Neurol. 2012 Jul;72(1):18-31. doi: 10.1002/ana.23634. Review.

PMID:
22829266

Supplemental Content

Support Center